Clinuvel Pharmaceuticals Limited (ASX:CUV)

Clinuvel Pharmaceuticals Balance Sheet

Financials in millions AUD. Fiscal year is July - June.

Assets

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022
Cash & Equivalents	21.39	28.02	35.2	31.89	121.51
Short-Term Investments	230.66	196.09	148.67	124.92	-
Cash & Short-Term Investments	252.06	224.11	183.87	156.81	121.51
Cash Growth	12.47%	21.88%	17.25%	29.05%	46.94%
Accounts Receivable	18.72	24.17	25.01	20.64	15.9
Other Receivables	4.74	3.3	1.23	1.57	0.3
Receivables	23.45	27.46	26.24	22.21	16.2
Inventory	6.88	8.82	10.63	9.52	1.83
Prepaid Expenses	-	-	-	-	1.04
Other Current Assets	2.24	2.58	1.33	1.07	-
Total Current Assets	284.63	262.97	222.06	189.62	140.58
Property, Plant & Equipment	9.25	7.13	7.72	2.85	2.7
Long-Term Investments	0.22	0.21	0.13	-	-
Goodwill	-	-	-	-	0.19
Other Intangible Assets	0.19	0.19	0.19	0.19	-
Long-Term Deferred Tax Assets	0.81	1.26	1.02	1.06	0.48
Total Assets	295.09	271.75	231.12	193.71	143.95

Liabilities

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022
Accounts Payable	1.28	2.55	2.35	2.79	0.26
Accrued Expenses	2.87	2.29	1.88	1.45	2.86
Current Portion of Leases	0.39	0.43	0.37	0.3	0.32
Current Income Taxes Payable	6.71	14.55	15.85	16.09	7.28
Other Current Liabilities	7.97	7.39	4.76	4.86	3.02
Total Current Liabilities	19.22	27.21	25.21	25.49	13.73
Long-Term Leases	1.55	0.1	0.51	0.7	0.94
Pension & Post-Retirement Benefits	0.12	0.13	0.08	0.06	0.03
Long-Term Deferred Tax Liabilities	1.19	3.42	2.23	2.76	3.62
Other Long-Term Liabilities	0.14	0.09	0.08	0.07	0.07
Total Liabilities	22.21	30.94	28.11	29.08	18.39

Shareholders' Equity

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022
Common Stock	172.31	169.28	168.8	151.85	151.85
Retained Earnings	95.04	63.63	29.96	-9.77	-38.4
Comprehensive Income & Other	5.53	7.9	4.25	22.56	12.11
Total Common Equity	272.88	240.81	203.01	164.63	125.56
Shareholders' Equity	272.88	240.81	203.01	164.63	125.56
Total Liabilities & Equity	295.09	271.75	231.12	193.71	143.95

Additional Metrics

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022
Total Debt	1.94	0.53	0.88	1	1.26
Net Cash (Debt)	250.12	223.58	182.99	155.81	120.25
Net Cash Growth	11.87%	22.18%	17.44%	29.57%	47.75%
Net Cash Per Share	4.93	4.44	3.59	3.01	2.32
Filing Date Shares Outstanding	50.43	50.12	50.08	49.41	49.41
Total Common Shares Outstanding	50.43	50.12	50.08	49.41	49.41
Working Capital	265.41	235.76	196.85	164.12	126.85
Book Value Per Share	5.41	4.80	4.05	3.33	2.54
Tangible Book Value	272.7	240.62	202.83	164.45	125.37
Tangible Book Value Per Share	5.41	4.80	4.05	3.33	2.54
Land	5.02	5.02	4.97	-	-
Machinery	2.01	2.19	1.94	1.53	1.33
Construction In Progress	1.24	-	-	-	-
Leasehold Improvements	1.99	1.99	1.99	1.89	1.25

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Aug 28, 2026

Data Sources Report a data error